Skip to main content

Non-lipid markers for CVD

Non-lipid markers for CVD

For some patients, the only indication of poor clopidogrel response to PLAVIX® (clopidogrel bisulfate) may be an atherothrombotic event, such as a heart attack or stroke. AccuType® CP enables early identification of patients who are predisposed to poor therapy response.

PLAVIX is indicated for the reduction of atherothrombotic events for patients with a history of recent myocardial infarction, stroke, or established peripheral arterial disease, as well as patients who are to be managed with percutaneous coronary intervention.1 It is marketed in the US under the trade name PLAVIX by Bristol-Myers Squibb and Sanofi-Aventis pharmaceuticals.2

This information is provided for informational purposes only and is not intended as medical advice. A physician’s test selection and interpretation, diagnosis, and patient management decisions should be based on his/her education, clinical expertise, and assessment of the patient.



  1. FDA approves new indication for Plavix® (clopidogrel bisulfate) offering new option for patients with most severe type of heart attack. Sanofi-Aventis. Accessed June 29, 2021.
  2. Sanofi-Aventis and Bristol-Meyers Squibb announce important updates to PLAVIX® U.S. prescribing information. Sanofi-Aventis. March 12, 2010. Accessed June 29, 2021.